aav-gad
Gene therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2003 (NCT00195143)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate decarboxylase 65 kDa isoformSupplementation
GAD2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav-gad
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05894343 | Phase 1/Phase 2 (Phase 2) | May 19, 2023 | MeiraGTx |
| NCT05603312 | Phase 1/Phase 2 (Phase 2) | Oct 5, 2022 | MeiraGTx |
| NCT00643890 | Phase 2 | Aug 1, 2008 | Neurologix, Inc. |
| NCT00195143 | Phase 1 | Aug 1, 2003 | Cornell University, Neurologix, Inc., University of Chicago |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MeiraGTx | For profit | 2 | 2 | 1 | 2022 |
| Neurologix, Inc. | For profit | 2 | 2 | 2 | 2003 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2003 |
4 organizations
Page 1 / 1